← board
CYAN
distress 2/10 · well-funded / low risk$0.530%today-7% from 52w high
Revenue
$13M
Liquidity
$1M
Runway
1.4 yrs
Shares 1y
+2%
Price & events
+32.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+3.9%
1W
+35.9%
1M
+35.9%
3M
+32.5%
6M
+26.2%
1Y
+3.9%
2Y
-82.9%
5Y
-83.5%
All
Overview
- Market Cap
- $3.92M
- Enterprise Value
- $4.27M
- Volume
- 0
- 52 Week Range
- $0.26 – $0.57
- Total Shares
- 7.39M
- Float Shares
- 4.85M
- Short %
- 0.00%
- % Held by Insiders
- 32.77%
- % Held by Institutions
- 0.00%
- Beta
- 0.14
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.